{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:18:43Z","timestamp":1780975123567,"version":"3.54.1"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>A 54-year-old woman with known chest wall melanoma (post\u2013wide local excision) presented for imaging after a yearlong therapy with nivolumab. <jats:sup>18<\/jats:sup>F-FDG PET\/CT was performed 1 day after she completed the immunotherapy. Maximum intensity projection images showed bilateral relatively symmetrical uptake in the facial region. On fused PET\/CT images, the uptake was seen corresponding to subcutaneous malar prominence underneath the orbits (like eye-black stripe used in sports) with subcutaneous malar calcification. Repeat PET\/CT performed after 3 months revealed significant decrease in the malar uptake. Interval resolution of the uptake likely suggested this being inflammatory and secondary to immunotherapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000002846","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T19:40:22Z","timestamp":1577216422000},"page":"217-219","source":"Crossref","is-referenced-by-count":4,"title":["\u201cEye-Black\u201d Sign Secondary to Nivolumab Immunotherapy"],"prefix":"10.1097","volume":"45","author":[{"given":"Sarv","family":"Priya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,24]]},"reference":[{"key":"bib2-20230925","doi-asserted-by":"crossref","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non\u2013small cell lung cancer","volume":"5","year":"2016","journal-title":"Oncoimmunology"},{"key":"bib3-20230925","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/CCO.0000000000000290","article-title":"Dermatologic complications of anti\u2013PD-1\/PD-L1 immune checkpoint antibodies","volume":"28","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"bib4-20230925","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti\u2013PD-1 therapy","volume":"60","year":"2016","journal-title":"Eur J Cancer"},{"key":"bib5-20230925","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s11864-016-0434-0","article-title":"Cutaneous complications of targeted melanoma therapy","volume":"17","year":"2016","journal-title":"Curr Treat Options Oncol"},{"key":"bib6-20230925","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors","volume":"19","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"bib7-20230925","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","year":"2019","journal-title":"Eur J Cancer"},{"key":"bib8-20230925","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","article-title":"Cutaneous adverse effects of the immune checkpoint inhibitors","volume":"41","year":"2017","journal-title":"Curr Probl Cancer"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002846","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:11:07Z","timestamp":1695622267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000002846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,24]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000002846","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12,24]]}}}